Hikma Pharmaceuticals PLC operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Hikma Pharmaceuticals PLC with three other
companies in this sector in the United Kingdom:
sales of £447.50 million [US$583.44 million]
of which 37%
was Licensing & Biotechnology),
Croda International Plc
(£1.24 billion [US$1.62 billion]
of which 34%
was Personal Care), and
(£786.93 million [US$1.03 billion]
of which 100%
was Buprenorphine Based Drugs).
Hikma Pharmaceuticals PLC reported sales of £1.45 billion (US$1.89 billion)
December of 2016.
increase of 53.6%
versus 2015, when the company's sales were £944.31 million.
Sales at Hikma Pharmaceuticals PLC have increased during each of the previous five years
(and since 2011, sales have increased a total of 154%).
Sales of Generic Pharmaceuticals saw an increase
that was more than double the company's growth rate: sales were up
353.7% in 2016, from
£99.02 million to £449.25 million.